Comparative pharmacokinetics of perfluorooctanesulfonate (PFOS) in rats, mice, and monkeys

Reproductive Toxicology

Volumn 33, Issue 4, 2012, Pages 428-440

  Chang, Shu Ching ^a   Noker, Patricia E ^b   Gorman, Gregory S ^b,c   Gibson, Sheila J ^a   Hart, Jill A ^a   Ehresman, David J ^a   Butenhoff, John L ^a  

^a 3M COMPANY   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c SAMFORD UNIVERSITY   (United States)

Author keywords

Mice; Monkeys; Perfluoroalkyls; Perfluorooctanesulfonate; PFOS; Pharmacokinetics; Rats

Indexed keywords

PERFLUOROOCTANESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD LEVEL; CONTROLLED STUDY; EXCRETION; EXPERIMENTAL MONKEY; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; FECES; FEMALE; HEALTH HAZARD; MALE; MOUSE; NONHUMAN; PLASMA HALF LIFE; RAT; SEX DIFFERENCE; SPECIES COMPARISON; TISSUE DISTRIBUTION; TOXICITY TESTING; TOXICOKINETICS; URINARY EXCRETION;

ADMINISTRATION, ORAL; ALKANESULFONIC ACIDS; ANIMALS; ENVIRONMENTAL POLLUTANTS; FECES; FEMALE; FLUOROCARBONS; HALF-LIFE; INJECTIONS, INTRAVENOUS; LIVER; MACACA FASCICULARIS; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED STRAINS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

ANIMALIA; MUS; RATTUS; RODENTIA;

EID: 84861528581     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2011.07.002     Document Type: Article

References (53)

1. Xu L., Krenitsky D.M., Seacat A.M., Butenhoff J.L., Anders M.W. Biotransformation of N-ethyl-N-(2-hydroxyethyl)perfluorooctanesulfonamide by rat liver microsomes, cytosol, and slices and by expressed rat and human cytochromes P450. Chem Res Toxicol 2004, 17(June (6)):767-775.
2. Schultz M.M., Higgins C.P., Huset C.A., Luthy R.G., Barofsky D.F., Field J.A. Fluorochemical mass flows in a municipal wastewater treatment facility. Environ Sci Technol 2006, 40(December (23)):7350-7357.
3. Schroder H.F., Jose H.J., Gebhardt W., Moreira R.F., Pinnekamp J. Biological wastewater treatment followed by physicochemical treatment for the removal of fluorinated surfactants. Water Sci Technol 2010, 61(12):3208-3215.
4. Hansen K.J., Clemen L.A., Ellefson M.E., Johnson H.O. Compound-specific, quantitative characterization of organic fluorochemicals in biological matrices. Environ Sci Technol 2001, 35(February (4)):766-770.
5. Giesy J.P., Kannan K. Global distribution of perfluorooctane sulfonate in wildlife. Environ Sci Technol 2001, 35(April (7)):1339-1342.
6. Wang T., Wang Y., Liao C., Cai Y., Jiang G. Perspectives on the inclusion of perfluorooctane sulfonate into the Stockholm convention on persistent organic pollutants. Env Sci Technol [Viewpoint] 2009, 43(14):5171-5175.
7. Houde M., Martin J.W., Letcher R.J., Solomon K.R., Muir D.C. Biological monitoring of polyfluoroalkyl substances: a review. Environ Sci Technol 2006, 40(June (11)):3463-3473.
8. Butenhoff J.L., Olsen G.W., Pfahles-Hutchens A. The applicability of biomonitoring data for perfluorooctanesulfonate to the environmental public health continuum. Environ Health Perspect 2006, 114(November (11)):1776-1782.
9. Lau C., Anitole K., Hodes C., Lai D., Pfahles-Hutchens A., Seed J. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Tox Sci 2007, 99(2):366-394.
10. Calafat AM, Wong LY, Kuklenyik Z, Reidy JA, Needham LL. Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and Comparisons with NHANES 1999-2000. Environ Health Perspect 2007;115(November (11)):1596-602.
11. Haug L.S., Thomsen C., Becher G. Time trends and the influence of age and gender on serum concentrations of perfluorinated compounds in archived human samples. Environ Sci Technol 2009, 43(6):2131-2136.
12. Spliethoff H.M., Tao L., Shaver S.M., Aldous K.M., Pass K.A., Kannan K., et al. Use of newborn screening program blood spots for exposure assesment: declining levels of perfluorinated compounds in New York state infants. Environ Sci Technol 2008, 42:5361-5367.
13. Olsen G.W., Mair D.C., Church T.R., Ellefson M.E., Reagen W.K., Boyd T.M., et al. Decline in perfluorooctanesulfonate and other polyfluoroalkyl chemicals in American Red Cross adult blood donors, 2000-2006. Environ Sci Technol 2008, 42(July (13)):4989-4995.
14. Kato K., Wong L.-Y., Jia L.T., Kuklenyik Z., Calafat A.M. Trends in exposure to polyfluoroalkyl chemicals in the U.S. population: 1999-2008. Environ Sci Technol 2011, doi:10.1021/es1043613.
15. Calafat A.M., Kuklenyik Z., Reidy J.A., Caudill S.P., Tully J.S., Needham L.L. Serum concentrations of 11 polyfluoroalkyl compounds in the U.S. population: data from the national health and nutrition examination survey (NHANES). Environ Sci Technol 2007, 41(April (7)):2237-2242.
16. Paul A.G., Jones K.C., Sweetman A.J. A first global production, emission, and environmental inventory for perfluorooctane sulfonate. Env Sci Technol 2009, 43(2):386-392.
17. Olsen G.W., Burris J.M., Ehresman D.J., Froehlich J.W., Seacat A.M., Butenhoff J.L., et al. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 2007, 115(September (9)):1298-1305.
18. Seacat A.M., Thomford P.J., Hansen K.J., Olsen G.W., Case M.T., Butenhoff J.L. Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol Sci 2002, 68(July (1)):249-264.
19. Benskin J.P., De Silva A.O., Martin L.J., Arsenault G., McCrindle R., Riddell N., et al. Disposition of perfluorinated acid isomers in Sprague-Dawley rats; part 1: single dose. Environ Toxicol Chem 2009, 28(March (3)):542-554.
20. De Silva A.O., Benskin J.P., Martin L.J., Arsenault G., McCrindle R., Riddell N., et al. Disposition of perfluorinated acid isomers in Sprague-Dawley rats; part 2: subchronic dose. Environ Toxicol Chem 2009, 28(March (3)):555-567.
21. Andersen M.E., Clewell H.J., Tan Y.M., Butenhoff J.L., Olsen G.W. Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys-Probing the determinants of long plasma half-lives. Toxicology 2006, 227(Ocotober (1-2)):156-164.
22. Loccisano A.E., Campbell J.L., Andersen M.E., Clewell H.J.I. Evaluation and prediction of pharmacokinetics of PFOA and PFOS in the monkey and human using a PBPK model. Regul Toxicol Pharmacol 2011, 59(1):157-175.
23. Sundstrom M., Ehresman D.J., Bignert A., Butenhoff J.L., Olsen G.W., Chang S.C., et al. A temporal trend study (1972-2008) of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in pooled human milk samples from Stockholm, Sweden. Environ Int 2011, 37(1):178-183.
24. 35S-labelled perfluorooctane sulfonate (PFOS) in C57Bl/6 mice following late gestational exposure. Reprod Toxicol 2010, 30(4):558-565.
25. 35S-labelled perfluorooctane sulfonate in adult mice after oral exposure to a low environmentally relevant dose or a high experimental dose. Toxicology 2011, 284:1-3. 54-62.
26. Chang S., Das K., Ehresman D.J., Ellefson M.E., Gorman G.S., Hart J.A., et al. Comparative pharmacokinetics of perfluorobutyrate (PFBA) in rats, mice, monkeys, and humans and relevance to human exposure via drinking water. Toxicol Sci 2008, 104:40-53.
27. Olsen G.W., Chang S.C., Noker P.E., Gorman G.S., Ehresman D.J., Lieder P.H., et al. A comparison of the pharmacokinetics of perfluorobutanesulfonate (PFBS) in rats, monkeys, and humans. Toxicology 2009, 256:1-2. 65-74.
28. Butenhoff J.L., Kennedy G.L., Hinderliter P.M., Lieder P.H., Jung R., Hansen K.J., et al. Pharmacokinetics of perfluorooctanoate in cynomolgus monkeys. Toxicol Sci 2004, 82(December (2)):394-406.
29. Sundström M., Chang S.-C., Noker P.E., Gorman G.S., Hart J.A., Ehresman D.J., et al. Comparative pharmacokinetics of perfluorohexanesulfonate (PFHxS) in rats, mice, and monkeys. Repro Toxicol 2012, 33:441-451.
30. ILAR. Guide for the Care and Use of Laboratory Animals. National Research Council, Institute of Laboratory Animal Resources. Washington, DC: National Academy Press; 1996.
31. Ehresman D.J., Froehlich J.W., Olsen G.W., Chang S.C., Butenhoff J.L. Comparison of human whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and other fluorochemicals. Environ Res 2007, 103(February (2)):176-184.
32. Chang S.C., Thibodeaux J.R., Eastvold M.L., Ehresman D.J., Bjork J.A., Froehlich J.W., et al. Negative bias from analog methods used in the analysis of free thyroxine in rat serum containing perfluorooctanesulfonate (PFOS). Toxicology 2007, 234(May (1-2)):21-33.
33. Chang S.C., Ehresman D.J., Bjork J.A., Wallace K., Parker G.A., Stump D.G., et al. Gestational and lactational exposure to potassium perfluorooctanesulfonate (K+PFOS) in rats: toxicokinetics, thyroid hormone status, and related gene expression. Reprod Toxicol 2009, 27:3-4. 387-99.
34. Seacat A.M., Thomford P.J., Hansen K.J., Clemen L.A., Eldridge S.R., Elcombe C.R., et al. Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology 2003, 183(February (1-3)):117-131.
35. Curran I., Hierlihy S.L., Liston V., Pantazopoulos P., Nunnikhoven A., Tittlemier S., et al. Altered fatty acid homeostasis and related toxicologic sequelae in rats exposed to dietary potassium perfluorooctanesulfonate (PFOS). J Toxicol Environ Health A 2008, 71(23):1526-1541.
36. Olsen G.W., Hansen K.J., Stevenson L.A., Burris J.M., Mandel J.H. Human donor liver and serum concentrations of perfluorooctanesulfonate and other perfluorochemicals. Environ Sci Technol 2003, 37(March (5)):888-891.
37. Johnson J.D., Gibson S.J., Ober R.E. Cholestyramine-enhanced fecal elimination of carbon-14 in rats after administration of ammonium [14C]perfluorooctanoate or potassium [14C]perfluorooctanesulfonate. Fundam Appl Toxicol 1984, 4(December (6)):972-976.
38. Elcombe CR, Elcombe BM, Foster JR, Chang S-C, Ehresman DJ, Butenhoff JL. Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPARα and CAR/PXR. Toxicology; in review.
39. Elcombe CR, Elcombe BM, Foster JR, Chang S-C, Ehresman DJ, Noker PE, et al. Evaluation of hepatic and thyroid responses in male Sprague Dawley rats for up to eighty-four days following seven days of dietary exposure to potassium perfluorooctanesulfonate. Toxicology; in review.
40. Han X., Yang C.H., Snajdr S.I., Nabb D.L., Mingoia R.T. Uptake of perfluorooctanoate in freshly isolated hepatocytes from male and female rats. Toxicol Lett 2008, 181(2):81-86.
41. Bijland S., Rensen P.C.N., Pieterman E.J., Maas A.C.E., van der Hoorn J.W., van Erk M.J., et al. Perfluoroalkyl sulfonates cause chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-Leiden.CETP mice. Toxicol Sci 2011, 123(1):290-303.
42. Griffith F.D., Long J.E. Animal toxicity studies with ammonium perfluorooctanoate. Am Ind Hyg Assoc J 1980, 41(August (8)):576-583.
43. Kudo N., Kawashima Y. Toxicity and toxicokinetics of perfluorooctanoic acid in humans and animals. J Toxicol Sci 2003, 28(May (2)):49-57.
44. Vanden Heuvel J.P., Davis J.W., Sommers R., Peterson R.E. Renal excretion of perfluorooctanoic acid in male rats: inhibitory effect of testosterone. J Biochem Toxicol 1992, 7(Spring (1)):31-36.
45. Kudo N., Suzuki E., Katakura M., Ohmori K., Noshiro R., Kawashima Y. Comparison of the elimination between perfluorinated fatty acids with different carbon chain length in rats. Chem Biol Interact 2001, 134(April (2)):203-216.
46. Kudo N., Katakura M., Sato Y., Kawashima Y. Sex hormone-regulated renal transport of perfluorooctanoic acid. Chem Biol Interact 2002, 139(March (3)):301-316.
47. Hinderliter P.M., Han X., Kennedy G.L., Butenhoff J.L. Age effect on perfluorooctanoate (PFOA) plasma concentration in post-weaning rats following oral gavage with ammonium perfluorooctanoate (APFO). Toxicology 2006, 225(August (2-3)):195-203.
48. Katakura M., Kudo N., Tsuda T., Hibino Y., Mitsumoto A., Kawashima Y. Rat organic anion transporter 3 and organic anion transporting polypeptide 1 mediate perfluorooctanoic acid transport. J Health Sci 2007, 53(1):77-83.
49. Weaver Y.M., Ehresman D.J., Butenhoff J.L., Hagenbuch B. Roles of rat renal organic anion transporters in transporting perfluorinated carboxylates with different chain lengths. Toxicol Sci 2010, 113(2):305-314.
50. Yang C.H., Glover K.P., Han X. Organic anion transporting polypeptide (Oatp) 1a1-mediated perfluorooctanoate transport and evidence for a renal reabsorption mechanism of Oatp1a1 in renal elimination of perfluorocarboxylates in rats. Toxicol Lett 2009, 190(October (2)):163-171.
51. Yang C.H., Glover K.P., Han X. Characterization of cellular uptake of perfluorooctanoate via organic anion transporting polypeptide 1A2, organic anion transporter 4, and urate transporter 1 for their potential roles in mediating human renal reabsorption of perfluorocarboxylates. Toxicol Sci 2010, 117(2):294-302.
52. Nakagawa H., Terada t, Harada K.H., Hitomi T., Inoue K., Inui K., et al. Human organic anion transporter hOAT4 is a transporter of perfluorooctanoic acid. Basic Clin Pharmacol Toxicol 2009, 105:136-138.
53. Kerstner-Wood C, Coward L, Gorman G. Protein binding of perfluorobutane sulfonate, perfluorohexane sulfonate, perfluorooctane sulfonate, and perfluorooctanote to plasma (human, rat, and monkey), and various human-derived plasma protein fractions. Southern Research Institute Study No. 9921.7. USEPA Administrative Record AR-226-1354; 2003.